Marc Espié
- Cancer Research top 0.5%
- Breast Cancer Treatment Studies 73
- Oncology top 0.5%
- Cancer Treatment and Pharmacology 49
- HER2/EGFR in Cancer Research 44
-
- Medical Imaging Techniques and Applications 24
- Radiomics and Machine Learning in Medical Imaging 17
-
- Breast Lesions and Carcinomas 25
-
- Advanced Breast Cancer Therapies 19
-
- Estrogen and related hormone effects 15
Marc Espié
170 papers receiving 5.7k citations
Peers
Comparison fields: 5 of 125
- Cancer Research 2.4k
- Oncology 3.0k
- Radiology, Nuclear Medicine and Imaging 1.9k
- Pathology and Forensic Medicine 675
- Pulmonary and Respiratory Medicine 942
Countries citing papers authored by Marc Espié
This map shows the geographic impact of Marc Espié's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marc Espié with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marc Espié more than expected).
Fields of papers citing papers by Marc Espié
This network shows the impact of papers produced by Marc Espié. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marc Espié. The network helps show where Marc Espié may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Marc Espié, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2019 | 2 | |
| 2 | 2017 | 63 | |
| 3 | 2017 | 9 | |
| 4 | 2016 | 6 | |
| 5 | 2015 | 49 | |
| 6 | 2015 | 31 | |
| 7 | 2014 | 18 | |
| 8 | 2014 | 3 | |
| 9 | Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer. | 2013 | 6 |
| 10 | 2013 | 47 | |
| 11 | 2013 | 211 | |
| 12 | 2013 | 79 | |
| 13 | 2012 | 91 | |
| 14 | 2011 | 7 | |
| 15 | 2010 | 41 | |
| 16 | 2004 | 188 | |
| 17 | [Hormonal replacement therapy in menopause after breast cancer: first french study]. | 1998 | 4 |
| 18 | La chimioprévention du cancer du sein | 1998 | 1 |
| 19 | 1996 | 129 | |
| 20 | 1990 | 295 |
About Marc Espié
Marc Espié is a scholar working on Cancer Research, Oncology, Pathology and Forensic Medicine, Radiology, Nuclear Medicine and Imaging and Dermatology, having authored 180 papers that have together received 5.8k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (73 papers), Cancer Treatment and Pharmacology (49 papers), HER2/EGFR in Cancer Research (44 papers), Breast Lesions and Carcinomas (25 papers), Medical Imaging Techniques and Applications (24 papers), Advanced Breast Cancer Therapies (19 papers), Radiomics and Machine Learning in Medical Imaging (17 papers) and Estrogen and related hormone effects (15 papers). The work is most often cited by research in Cancer Research (2.4k citations), Oncology (3.0k citations), Radiology, Nuclear Medicine and Imaging (1.9k citations), Pathology and Forensic Medicine (675 citations) and Pulmonary and Respiratory Medicine (942 citations). Marc Espié has collaborated with scholars based in France, United States and Spain. Frequent co-authors include M. Marty, Sylvie Giacchetti, David Groheux, Elif Hindié, Anne de Roquancourt, C. Cuvier, Laëtitia Vercellino, Anne‐Sophie Hamy, Philippe Bertheau and Jacqueline Lehmann‐Che. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Cancer Research, European Journal of Nuclear Medicine and Molecular Imaging and Journal of Nuclear Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.